Comparative review of selected health technology assessment agencies:Features and insights for health technology assessment development and improvementOA
Health technology assessment(HTA)is increasingly used to guide coverage and pricing decisions,but many countries lack formal HTA agencies or rely on fragmented processes.This study aims to compare institutional and procedural features of selected HTA agencies and to derive policy options for establishing,institutionalising,or reforming HTA in diverse health systems.Using the World Health Organization(WHO)’s five-component institutionalisation framework,researchers completed a comparative narrative review of ten HTA systems.Thirty-five structural and procedural elements were extracted and synthesised into five analytical modules covering governance,assessment methods,institutional roles,lifecycle integration,and stakeholder engagement to enable structured cross-country comparison.HTA functions,authority,and processes varied widely.Independent agencies undertook broader mandates,whereas ministry-based units were more closely linked to reimbursement and policy implementation.Assessment relied on hybrid internal-external evidence review models,followed by formal appraisal or deliberation in all systems.Binding coverage outcomes were observed in England,France,Germany,and Brazil,although the legal force and implementation pathway differed across agencies.Pricing negotiation arrangements differed but were commonly linked to appraisal outputs.Horizon scanning,early scientific advice,and disinvestment mechanisms were unevenly implemented,while few systems employed lifecycle-oriented practices.HTA systems differ widely in governance,scope,and authority,and these differences shape their influence on pricing and reimbursement policies.Strengthening statutory integration,analytical capacity,and transparent engagement,especially where HTA is emergent or fragmented,is essential for legitimacy and sustainability.This study offers transferable options for settings without formal HTA agencies and may guide reforms towards sustainable and equitable health system goals.
Zonglin Dai;Effie Ka Yue Cheung;Ting Wang;David Makram Bishaie;Lei Si;Benjamin Hon Kei Yip;Yingyao Chen;Ian Chi Kei Wong;Andrew J.Mirelman;Manuel Antonio Espinoza;Xue Li
Department of Medicine,School of Clinical Medicine,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Hong Kong SAR,999077,China Centre for Safe Medication Practice and Research,Department of Pharmacology and Pharmacy,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Hong Kong SAR,999077,China The University of Hong Kong-Shenzhen Hospital,Shenzhen,Guangdong,518053,ChinaDepartment of Medicine,School of Clinical Medicine,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Hong Kong SAR,999077,China Centre for Safe Medication Practice and Research,Department of Pharmacology and Pharmacy,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Hong Kong SAR,999077,ChinaCentre for Innovation in Regulatory Science(CIRS),London,EC3A 8BE,UKSchool of Public Health,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Hong Kong SAR,999077,ChinaSchool of Health Sciences,Western Sydney University,Campbelltown,NSW 2560,Australia Translational Health Research Institute,Western Sydney University,Penrith,NSW 2751,AustraliaJockey Club School of Public Health and Primary Care(JCSPHPC),The Chinese University of Hong Kong,Hong Kong SAR,999077,ChinaSchool of Public Health,Fudan University,Shanghai,200032,ChinaCentre for Safe Medication Practice and Research,Department of Pharmacology and Pharmacy,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Hong Kong SAR,999077,China Aston Pharmacy School,Aston University,Birmingham,B47ET,UK School of Pharmacy,Medical Sciences Division,Macao University of Science and Technology,Macao SAR,999078,China Advanced Data Analytics for Medical Science Limited,Hong Kong SAR,999077,ChinaDepartment of Health Financing and Economics,World Health Organization,Geneva,CH-1211,SwitzerlandSchool of Public Health,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Hong Kong SAR,999077,ChinaDepartment of Medicine,School of Clinical Medicine,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Hong Kong SAR,999077,China Centre for Safe Medication Practice and Research,Department of Pharmacology and Pharmacy,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Hong Kong SAR,999077,China The University of Hong Kong-Shenzhen Hospital,Shenzhen,Guangdong,518053,China
医药卫生
HealthtechnologyassessmentInstitutionalgovernanceCoverageandpricingLifecyclemanagementStakeholderengagement
《Pharmacoeconomics and Policy》 2026 (2)
P.60-68,9
supported by the Research Impact Fund,Research Grants Council,University Grants Committee of the Hong Kong SAR,China(Project No.:R7007-22F).
评论